From Seekingalpha · · 40s
Ionis Pharmaceuticals Stock Plunges After Q3 Earnings
Ionis Pharmaceuticals stock drops 25% following Q3 earnings that missed Tryngolza sales targets.
In brief
Ionis Pharmaceuticals stock drops 25% following Q3 earnings that missed Tryngolza sales targets. Ionis Pharmaceuticals stock fell 25% after Q3 earnings showed slower-than-expected Tryngolza uptake and competitive pressures. Originally reported by Seekingalpha.
Q3 Earnings Impact
Ionis Pharmaceuticals stock plunged over 25% after Q3 earnings despite beating revenue and EPS expectations.
Sales Guidance Cut
IONS slashed 2026 Tryngolza sales guidance by more than half due to slower uptake and competitive pressures.
Confidence Erosion
Major clinical and commercial setbacks in 2026 have eroded confidence in IONS' transition to mainstream biopharma.
What it means
Ionis Pharmaceuticals stock fell 25% after Q3 earnings showed slower-than-expected Tryngolza uptake and competitive pressures.
